AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06585956 — intervention group
Intervention type: BEHAVIORAL
Intervention: Information
Description: Informing the patient and their relatives
Study NCT06088069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Patients will be virtually immersed into a natural universe and soft music for 15 minutes preoperatively and during surgery.
Study NCT05285371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinalysis (UA)
Description: Urinalysis will be performed twice daily starting on Postoperative Day 0.
Study NCT05285371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Urinalysis (UA)
Description: Urinalysis will be performed twice daily starting on Postoperative Day 0.
Study NCT05285371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Complete Metabolic Panel (CMP)
Description: A CMP will be performed on Postoperative Day 2 and Postoperative Day 4.
Study NCT05285371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Complete Metabolic Panel (CMP)
Description: A CMP will be performed on Postoperative Day 2 and Postoperative Day 4.
Study NCT05285371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucose Stick Test (d-Stick)
Description: A d-Stick will be performed twice daily except on Postoperative Day 2 and Postoperative Day 4 as the CMP includes serum glucose levels.
Study NCT05285371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Glucose Stick Test (d-Stick)
Description: A d-Stick will be performed twice daily except on Postoperative Day 2 and Postoperative Day 4 as the CMP includes serum glucose levels.
Study NCT05285371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: A medical chart review will be performed for all subjects enrolled.
Study NCT05285371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medical Chart Review
Description: A medical chart review will be performed for all subjects enrolled.
Study NCT06598111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amplified Benefits
Description: Participants write a brief, detailed narrative describing a day in their future if they did not restrict their caloric intake and were not concerned about their body weight or shape.
Study NCT06598111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amplified Consequences
Description: Participants complete the Pros and Cons of Anorexia scale to amplify the consequences of restrictive eating. They are also presented with blurbs about the consequences of restrictive eating.
Study NCT06598111 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants write a brief narrative considering a future free of concern about finances.
Study NCT05038098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Description: Undergo surgery
Study NCT05038098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Given peritumorally
Study NCT05038098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron Conjugated Polymers in Saline Suspension
Description: Given peritumorally
Study NCT05320445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Expressive Group Therapy
Description: The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
Study NCT06604455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure/relaxation with acupuncture
Description: The acupressure/acupuncture points will be designated based on evidence-based research. For example, clinical guideline-based integrative oncology protocol for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
Study NCT06604455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure/relaxation
Description: The acupressure points will be designated based on evidence-based research. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
Study NCT05387239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VL-PX10 and VL-P22 plus standard care
Description: The treatment consists of administration of VL-P22 and VL-PX10 plus standard care
Study NCT05387239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline plus standard care
Study NCT05092100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual stimulus similarity
Description: Visual stimulus similarity will be varied in order to test for effects on memory. Learning protocol (the order and frequency with which stimuli are learned) will also be varied.
Study NCT05092100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI will be used to measure patterns of BOLD activity during learning.
Study NCT05092100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye tracking
Description: Eye tracking will be used to measure patterns of eye movements when viewing images.
Study NCT05170919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Patients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.
Study NCT05170919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: the participant will be prescribed a dosage of 2.5mg per day if > 65 yrs. and 5 mg/per day if \<65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.
Study NCT06139016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality gear and content will be used to affect and control the audiovisual perception of patients during a single treatment with ketamine/esketamine
Study NCT04911140 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation twice a week
Description: The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, twice a week, for 4 weeks.
Study NCT04911140 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation three times a week
Description: The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, three times a week, for 4 weeks.
Study NCT04911140 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simulated Photobiomodulation
Description: Photobiomodulation will be simulated, with the device turned off, twice a week, for 4 weeks. The characteristic sound of the device will be triggered by recording.
Study NCT04912258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans arterial chemoembolization with Irinotecan Drug-eluting Beads
Description: preoperative chemoembolization with Irinotecan Drug-eluting Beads
Study NCT05686902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLEANING SOLUTION
Description: The difference in peristomal skin integrity between the groups will be examined.
Study NCT05686902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CLEANING SOLUTION
Description: The difference in peristomal skin integrity between the groups will be examined.
Study NCT03878251 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative attention evaluation criteria in intellectual disability
Description: Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)
Study NCT05589948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle Calm Study Placebo Control 1
Description: Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.
Study NCT05589948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle Calm Study Placebo Control 2
Description: Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.
Study NCT05589948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle Calm Study Active Product 1.1
Description: Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.
Study NCT05589948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle Calm Study Active Product 2.1
Description: Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.
Study NCT05589948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle Calm Study Active Product 2.2
Description: Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.
Study NCT04826861 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SLIM intervention
Description: Core components: 1) goal setting, 2) motivational interviewing, 3) feedback, 4) health technology
Study NCT06153927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT-FFR
Description: CT-FFR was calculated using HeartMedi+ 1.0 according to the manufacturer's instructions
Study NCT05019326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andrographis Paniculata
Description: Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
Study NCT05019326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boesenbergia
Description: Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
Study NCT05019326 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard supportive treatment
Description: as recommended by guidelines from the Ministry of Public Health, Thailand. No antivirus was given.
Study NCT06327269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib 10 mg
Description: Lenvatinib would be used on patients with advanced liver cancer after Liver transplantation as an adjuvant treatment.
Study NCT05270720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell
Description: Biological: Dendritic Cell Immunotherapy Adult patients with histopathologically diagnosed Ovarian Cancer will be eligible for this novel, personalized dendritic cell vaccine during course of standard of care chemotherapy.~If unacceptable side effects are observed at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 2.5x106.~If no unacceptable side effects are identified at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1X107.
Study NCT06271577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AliveCor 12-lead ECG
Description: The primary objective of this study is to determine if the AliveCor 12-lead Smartphone ECG is an acceptable substitute for a standard 12-lead ECG in the identification of STEMI and NSTEMI.
Study NCT05533606 — intervention group
Intervention type: DRUG
Intervention: Beta-Lactam Drugs
Description: During hospitalization，patients used Beta-Lactam drugs.
Study NCT04909996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinox--Group A
Description: GROUP A: Sentinox treatment performed 3 times/day for 5 days (as addon to the standard therapy) at 8am, 2pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment).
Study NCT04909996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinox--Group B
Description: GROUP B: Sentinox treatment performed 5 times/day for 5 days (as addon to the standard therapy) at 8am, 11am, 2pm, 5pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment).
Study NCT04312178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cash incentive
Description: cash incentive (20€ gift card)
Study NCT04312178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04312178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: return vaginal self-swab kit in person
Description: hand-delivered to a health care professional to encourage discussion of cervical cancer prevention
Study NCT05625113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuroprosthesis
Description: Use at least one time every day the gripping neuroprosthesis in daily life activities.
Study NCT05129553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Béa Applicator and Béa Cervical Cap Device
Description: Single-use of the investigational device
Study NCT05331963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio tape is designed in a specific way that it mimics the human skin nature. It more or less has the same width as the epidermis layer and can be stretched upto 40% of its resting length.Clinically, kinesio tape (KT) is used both alone and with other physiotherapeutic interventions, mainly for the pain control, to reduce inflammation, and to improve functional activity in patients with shoulder pain
Study NCT06507202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: General anesthesia is induced and maintained by continuous infusion of remimazolam and remifentanil, and recovered with flumazenil.
Study NCT06507202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia is induced and maintained by continuous infusion of propofol and remifentanil.
Study NCT05373160 — intervention group
Intervention type: OTHER
Intervention: Assessment study
Description: Assessment of functional tests with and without dual tasks
Study NCT06387368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Huaier Granules: Oral administration, 10g once, 3 times a day. Capecitabine: oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
Study NCT06387368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
Study NCT05481151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (Ropeginterferon alfa-2b-njft)
Description: Ropeginterferon alfa-2b-njft
Study NCT05481151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropeginterferon alfa-2b-njft (P1101)
Description: Ropeginterferon alfa-2b-njft
Study NCT06491277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flossband
Description: The use of Flossband (Sanctband COMPRE Floss 5.1 cm × 3.5 m; Sanct Japan Co., Ltd.), made of natural rubber, was applied starting from 5 cm below the ankle joint line with a 50% stretch. The band tension was increased to 70-75% around 2 cm above the attachment point of the Achilles tendon.
Study NCT06491277 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Controlled Group
Description: Cramer Tape Underwrap (7cm X 27m) foam bandage was applied starting 5 cm below the ankle joint line without tension. The control group received the same exercise protocol as the study group.
Study NCT04247685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-lead ECG monitoring device (MiRTLE Medical)
Description: 12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical is the experimental device;
Study NCT04247685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3-lead ECG gating system
Description: 3-lead ECG gating system is the placebo/standard of care
Study NCT04533503 — intervention group
Intervention type: DEVICE
Intervention: HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter
Description: Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.
Study NCT06347887 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ColonAiQ test and Colonoscopy
Description: Diagnostic Test
Study NCT04710160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel fast-setting calcium silicate cement (Protooth)
Description: In form of power and liquid to be mixed together to form a paste.
Study NCT04710160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novel fast-setting calcium silicate cement (Protooth)
Description: In form of power and liquid to be mixed together to form a paste.
Study NCT06359691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-focused strategies
Description: Patient-focused strategies to increase HTN management practices:~1. Hypertension registry: notify patients of their status, target education and resources to patients~2. Home BP monitoring: provide BP monitors, encourage reporting of home BP readings~3. Enhance standardization of home and office BP readings: patients trained by care staff, posters in clinics on how to measure BP correctly~4. Nurse-directed BP medication titration with CHW/Health Educator reinforcement: self-directed referrals to nurse-directed clinics and CHW/health educators~5. Enhance patient understanding of BP using culturally- and linguistically- tailored materials: tailored educational materials offered to patients in clinic, via text and the patient portal.~6. Social needs screening and linkage to community resources: awareness of and self-referrals to community resources~7. Behavioral science intervention messaging: posters in clinic waiting rooms, scripts for RN/PCP, texts to patients
Study NCT06359691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider-focused strategies
Description: Provider-focused strategies to increase HTN management practices:~1. Hypertension registry: identify patients with uncontrolled BP, notify care team~2. Home BP monitoring: provide home BP monitors, encourage reporting of BP readings~3. Enhance standardization of home/office BP readings: staff training, posters in clinic~4. Simplify treatment protocols using fixed-dose combo meds: education on fixed-dose combo meds~5. Nurse-directed BP med titration w/ CHW/Health Educator support: system for team-based care, referral to nurse-directed clinics \& CHWs/health educators~6. Enhance patient understanding of BP using culturally- and linguistically- tailored materials: Increased availability of tailored materials~7. Social needs screening and linkage to community resources: referral system to resources~8. CHW assigned to patients with complex medical and social needs: referral of complex patients to CHWs~9. Behavioral science messaging: posters in charting rooms, scripts for RNs
Study NCT06359691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient- and provider-focused strategies
Description: A combination of the 7 patient-focused strategies (see patient-focused strategies outlined above) and 9 provider-focused strategies (see provider-focused strategies outlined above) implemented simultaneously.
Study NCT06609694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable oxygen concentrator Inogen G5 model
Description: The concentrator weighs 4.7 lbs. and has a battery life of 13 hours. It has 6 settings with 1 providing the lowest pulse flow and 6 provides the highest flow. The setting will be increased every 30 minutes by 1 when oxygen nadir is lower than 94% and or obstructive index is ≥ 5 /hour.
Study NCT05077085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Description: single intravenous infusion of bezlotoxumab 10 mg/kg
Study NCT05077085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation (FMT)
Description: single infusion of 198 cc fecal suspension (derived from 60g donor feces) via duodenal tube or coloscopy
Study NCT05077085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin oral
Description: 14 days vancomycin oral 125mg QID (250mg QID when 125mg not available)
Study NCT05077085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin oral
Description: 14 days vancomycin oral 125mg QID (250mg QID when 125mg not available)
Study NCT05162989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCare HOME2 vs iCare IC200
Description: Measurement of IOP with iCare HOME2 compared with iCare IC200.
Study NCT06300450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Alert
Description: On-screen alert-based decision support raising awareness of need for lipid-lowering therapy in patients with peripheral artery disease